Audit 31104

FY End
2022-06-30
Total Expended
$39.81M
Findings
4
Programs
206
Organization: Kennedy Krieger Institute (MD)
Year: 2022 Accepted: 2023-03-21

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
34560 2022-001 - Yes L
34561 2022-001 - Yes L
611002 2022-001 - Yes L
611003 2022-001 - Yes L

Programs

ALN Program Spent Major Findings
12.750 Reliable Sensor Technology-Based for Rehabilitation $962,700 - 0
93.110 McH Training Program in Neurodevelopment Disabilities $712,922 - 0
93.632 Developmental Disabilities $577,352 - 0
84.324A Development of An Intervention for Center-Based Early Childhood Education $460,945 - 0
93.600 Early Head Start Center $431,405 Yes 0
93.286 Novel Approaches for Cest Labeling, Detection, Quantification and Translation $427,422 - 0
93.994 Within My World $399,842 - 0
93.255 Children's Hospital Graduate Medical Education $387,713 - 0
93.837 Mri Based Phosphocreatine Mapping Method to Assess Patients with Peripheral Arterial Disease $352,360 - 0
93.242 Anomalous Motor System Physiology in Adhd $314,143 - 0
93.243 Collective for Antiracist Child and Family Systems $288,431 - 0
93.600 Pact Ehs Therapeutic Nursery $250,504 Yes 0
16.575 Underserved Victims Project $227,664 Yes 0
93.279 Healthy Brain & Child Development National Consortium $222,078 - 0
93.853 Chromatin Modifications in Gbm-Propagating Cells $212,196 - 0
93.242 Behavioral and Neural Representations of Subjective Effort Cost $211,553 - 0
93.286 Development and Translation of D-Glucose As A Diagnostic Agent for Mri $210,147 - 0
93.000 Therapeutic Nursery $200,691 - 0
84.027 Providing Technical Assistance to the Eastern Shore of Maryland $199,786 - 0
84.324A Developing Early Achievements for Pre-K Children with Developmental Language Disorders $193,836 - 0
93.286 Resource for Molecular Imaging Agents in Precision Medicine $181,681 - 0
93.351 Magnetic Particle Imaging Scanner $180,000 - 0
93.286 Gastric Electrical Slow Wave Functional Mri of the Human Brain $178,100 - 0
93.242 Neurobiology of Social Behavior Circuit Analysis in Early Life $177,927 - 0
93.853 Gabaergic Sensorimotor Dysfunction in Tourette Syndrome $168,528 - 0
93.137 Emurg for Health Equity Leaders Fellowship Program $161,017 - 0
93.865 Preparing for A Clinical Trial in Kabuki Syndrome $160,944 - 0
93.853 In Vivo Assessment of Meningeal Inflammation and It's Clinical Impact in Ms $139,642 - 0
93.865 Mechanism & Rehabilitation of Cerebella Ataxia $133,881 - 0
93.853 Utility of Advanced Mri & Wearable Technology to Identify Lbsl $133,852 - 0
93.865 Subtle Motor Functioning and Functional Connectivity in Youth After Mild Tbi $133,140 - 0
93.310 An Asf Enriched Risk Echo Cohort $128,644 - 0
93.994 Enhancing Child Care for Children $125,530 - 0
93.994 Project Stir $124,050 - 0
93.865 Mechanisms Regulating Kcc@ Hypofunction $122,543 - 0
93.866 Biomarkers of Cognetive Decline Among Normal Individuals $116,397 - 0
93.242 Neural Mechanisms of Hiv Associates Cns Dysfunction $109,706 - 0
93.847 Developing Mri Contrast Agents to Detect Progression in Renal Disease $108,970 - 0
47.040 Multimodal Algorithms for Notor Imitation Assesment in Autism $108,931 - 0
93.394 Noninvasive Prediction of Tumor Response to Gemcitabine Using Mri $105,094 - 0
93.837 Non-Contrast-Enhanced Velocity-Selective Mr Angiography $104,504 - 0
93.865 Measuring Altered Glutathione in Children with Austism $95,983 - 0
93.286 Sensitivity Enhanced Mri Imaging of Receptor Binding in Breast Cancer $94,889 - 0
93.394 Quantitative Cest Mri for Gbm Ealry Response Prediction and Biopsy Guidance $94,001 - 0
93.837 Mri Bimodal Imaging for Non Invasive Tracking of Extracellular Vesicles $92,073 - 0
93.242 Somatossensory Inhibitory Dysfunction in Austism Spectrum Disorder $90,287 - 0
93.853 Preclinical Stroke Trial with the Parp Inhibitor Veliparib $89,084 - 0
93.279 Developing Plans for A Baltimore Site If the Healthy Bcd Study $89,058 - 0
84.425R Covid-19: Coronavirus Response & Relief Supplemental Appropriations Act - Geer $86,748 - 0
93.837 Velocity-Selective Arterial Spin Labeling Based Perfusion Mapping for Cerebrovascular Diseases $84,000 - 0
93.434 Promoting Positive Outcomes for Infant & Toddlers $81,563 - 0
93.630 Enhancing Advocacy & Public Policy Work Project $81,476 - 0
93.307 Social Adversities, Epigenetics and the Obesity Epidemic $79,970 - 0
93.837 Computational Assessment of Galectin-3 Significance in Heart Failure $78,942 - 0
93.853 Molecular Determinanats of Cellular Heteroeneity and Theapeutic Resistance in Gbm $78,595 - 0
83.837 Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest $76,723 - 0
93.853 Child Neurologist Career Development Program $75,135 - 0
93.853 The Global Leukodystrophy Initiative Clinical Trials Network $74,867 - 0
93.866 Impaired Cerebral Glucose Uptake in the Brain As An Mri Marker for Alzheimer's Disease $74,277 - 0
93.866 Brain Oxygen Consumption As An Mri Biomarker $73,181 - 0
93.242 Motion-Robust Brain Mri for Infants $72,888 - 0
10.555 School Lunch Program $71,513 - 0
93.846 Brittle Bone Disorders Consortium of the Rare Disease Clinical Network $70,991 - 0
93.853 Development of Mechanisms Underlying Human Motor Learning $70,897 - 0
93.310 Supporting the Health & Well-Being of Children with Intellectual & Developmental Disability During Covid $69,734 - 0
93.394 Amide Proton Transfer Mri of Brain Tumors at 3t $69,620 - 0
93.310 Environmental Influences on Child Health Outcomes $68,985 - 0
93.395 Gene Delivery Nanoparticles to Treat Glioblastoma $68,132 - 0
12.420 Assessing Arrhythmic Risk in Adult Patients with Duchenne Muscular Dystrophy $64,114 - 0
93.853 Imaging Brain Glucose Uptake by in Vdmp Mri in Huntington's Disease $63,977 - 0
12.420 Randomized Trial of Telehealth Parent-Implemented Intervention $59,673 - 0
93.839 Clinical and Neuroimagin Phenotypes of Neurological Disorders in Pediatric Sickle Cell Disease $59,273 - 0
93.853 Advanced Mri Biomarkers in Hd Mouse Models Translatable to Humans $58,824 - 0
93.498 Covid-19: Provider Relief Fund & American Rescue Plan (arp) Rural Distribution $58,327 Yes 1
93.853 Advanced Mri Studies of Cerebrovascular & Lymphatic Abnormalities $56,720 - 0
93.866 Transcranial Direct Current Stimulation on Typical & Atypical Alzheimer's Disease $54,716 - 0
93.853 Extramural Research Programs in the Neurosciences Disorders $52,144 - 0
84.181A Baltimore City Infants & Toddlers Program $51,582 - 0
93.397 Non-Invasive Tracking of Genome-Corrected Ips Cells in Als $50,142 - 0
93.853 Bioenergetic Failure Underlies Cerebral Dysmaturity After Perinatal Brain Injury $48,126 - 0
93.600 Pact Ehs Therapeutic Nursery - Covid 19 Fund $47,921 Yes 0
93.847 Impact of Hypothalamic Gliosis on Appetite Regulation & Obesity Risk $44,740 - 0
12.420 Alzheimers Research Program $44,602 - 0
93.395 Image-Guided Combotherapies for Radiotherapy Induced Neurocognitive $42,959 - 0
93.866 Non-Contrast Mr Imaging of Blood-Brain-Barrier Permeability in Alzheimer's Disease $40,994 - 0
93.866 Contributions of Local Cerebral Iron to Cognitive Decline During Aging and Preclinical Alheimer's Disease $40,540 - 0
93.273 Stress and Chronic Alcohol Interactions $39,827 - 0
93.994 Genetics Laboratory $38,329 - 0
12.420 Mapping of Brain Gaba Levels in Tuberous Sclerosis Complex Using High-Resolution Proton Imaging $37,079 - 0
93.839 Neuroimaging, Neurogognitive & Plasma Pretein Markers in Sickle Cell $36,928 - 0
93.242 Visual Hallucinations & Memory Impairment in Parkinson's Disease $36,572 - 0
93.632 Covid-19: Expanding Disabilities Networks Access to Covid 19 Vaccines $36,499 - 0
93.242 Adolescent Changes in Brain and Behavior in Boys and Girls with Adhd $36,077 - 0
93.865 Early Childhood Constraint Therapy for Sensory Impairment $36,023 - 0
93.286 Intracellular Self-Assembly of Theranostic Nanoparticles for Imaging $35,686 - 0
93.732 Behavioral Health Workforce Education and Training Program $35,290 - 0
93.631 Center for Dignity in Heakthcare for People with Disabilities $35,244 - 0
93.242 A Novel Framework for Impaired Imitation in Asd $35,154 - 0
93.853 Biomarkers of Brain Injury in Criticlly Ill Children on Extracorporeal Membrance Oxygenation Ecmo $35,019 - 0
93.866 Advanced Mr Imaging of Olfactory Impairment in Prodromal Alzheimers Disease $34,838 - 0
93.866 Jh Alzheimer's Disease Research Center $34,830 - 0
93.421 Covid 19: Addressing Covid-19 Vaccine Access and Confidence Among People with Disabilites $34,423 - 0
93.243 Pediatric Integrated Care Collabrative $34,301 - 0
93.865 Adult Biomarkers in Neonatal Brain Injury $34,256 - 0
93.242 Examinatin of Developmental Trajectories of Cognitive, Motor, & Emotional Control $33,321 - 0
93.853 Development of Novel Functional Markers for Tbi Using Molecular Mri $32,478 - 0
93.853 Development of Mri Microvascular Biomarkers in Cognitive Impairment and Dementia $30,958 - 0
93.853 Paracrine Angiotensin II Signaling Promotes Medulloblastoma $29,885 - 0
93.853 Modeling Host Susceptibility Factors in Acute Flaccid Myelitis $29,224 - 0
93.242 Visual-Motor Development in Infants at High Risk for Autism $28,417 - 0
93.073 Centers for Autism & Developmental Disabilities Research $27,998 - 0
93.866 Towards A Comprehansive Neurometabolic Profile in Patients W/ Mild Cognitive Impairment $26,366 - 0
93.853 The Role of Ranbp2 in the Pathogenesis of Acute Encephalopathy $25,323 - 0
93.456 Maternal Child Health Careers/research Initatives-Undergrad $24,948 - 0
93.853 A Placebo Controlled Effectivemess in Inph Shunting Trial $24,865 - 0
93.110 McH Research $24,534 - 0
93.853 Cortical Functional Connectivity As An Early Biomarker of Recovery in Sci $24,013 - 0
93.865 Resident Training in Brain Injury Rehab $23,179 - 0
93.853 A Safety and Efficacy Study of Aava-Haadc $23,115 - 0
93.853 Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells $23,112 - 0
93.676 Residential Shelter Care & Fingerprinting Services $22,826 - 0
10.553 School Breakfast Program $22,537 - 0
93.242 Solving the Mri Motion Problem with Framewise Integrated Real Time Mri Monitoring Software $22,479 - 0
93.853 Extramural Research Programs in the Neuro Disorders $22,113 - 0
93.853 Imaging Neurodegeneration in Ms $20,979 - 0
12.420 Identifying the Underlying Mechanisms of Persistent Neurologic Symptoms $19,845 - 0
93.866 Blood Brain Barrier Dysfunction in Alzheimers Disease $19,755 - 0
93.394 Precision Magnetic Hypertermia by Integrating Magnetic Particle $19,026 - 0
93.853 Meaningful Outcomes & Multisite Readiness for Clinical Trials in Juvenile Neuronal Ceriod Lipofuscinosis $18,302 - 0
93.310 Wuiddrc and Kki Safe Return to School $18,202 - 0
93.865 Subjective Valuation of Ohysical Effort in Health and Disease $17,581 - 0
93.866 Developing Protein-Based Biomarkers for Alzheimer's Disease $17,148 - 0
93.866 Longitudinal Molecular Imaging of Neuropathology $15,384 - 0
93.865 Csa As A Preventable Public Health Problem $14,594 - 0
93.853 Move - Modeling of Fast Movement for Enhancement Via Neuroprosthetics $14,572 - 0
93.394 A Wireless Multi-Function Microscope for Lifetime Imaging of the Brain Tumor Vasculome $14,477 - 0
93.853 Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming $14,164 - 0
93.865 Intellectual and Developmental Disablities Research Centers 2013 $14,056 - 0
93.853 Targeted Therapies for Neonatal White Matter Injury $13,301 - 0
93.865 Identifying Precursors to Severe Problem Behavior $13,300 - 0
93.575 Child Care Stabilization Funds American Rescue Plan $13,032 - 0
93.286 Chemical Exchange Satuation Transfer Mr Fingerprinting $12,758 - 0
84.173 Pact: World of Care Child Care Center $12,665 - 0
93.853 Characterization & Validation of Cvr As A Biomarker $12,516 - 0
93.853 Clinical Readiness to Solve Barriers to Drug Development in Fshd $12,450 - 0
21.027 Covid-19: Providing Emergency Relief for Community Providers of Services to Individuals with Disablities - Covid $12,363 - 0
93.310 Non-Invasive Tracking of Genome-Corrected Ips Cells in Als $12,358 - 0
84.027 State Grant - B - Kodem Kol $12,000 - 0
47.041 Discovering Network Structure in the Space of Group Level Functional Differences $11,888 - 0
93.600 Southeast Baltimore Ehs $11,883 Yes 0
84.173 Pact: Helping Children W/special Needs Therapeutic Nursery -YMCA $11,639 - 0
93.865 The Role of Executve Functions in Reading and Remediation $11,262 - 0
93.286 Mri Resource for Physiologic, Metabolic & Anatomic Biomarkers $10,893 - 0
21.027 2021 Balt Nonprofit Relief Fun $10,000 - 0
93.866 Altered Ph in Early Alzheimers Disease Detected by Creatine $9,440 - 0
93.853 Development of An Mri Template & Neuroimaging Biomarkers $8,647 - 0
84.424A Covid-19: Building School Psychologist's Knowledge, Skills, and Practice to Support Education - Covid $8,455 - 0
93.073 Study to Explore Early Development $8,292 - 0
93.853 Imaging Small Blood and Lympahtic Vessel Abnormalities $8,092 - 0
93.866 Alzheimer's Disease Neuroimaging Initiative $7,595 - 0
93.866 Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers $7,578 - 0
93.286 Resources for Quantitive Functional Mri $7,069 - 0
93.853 Trial Readiness in Cavernous Angiomas and Symtomatic Hemmorage $6,845 - 0
93.310 Illuminationg Brain Function During Imitation in Children with Asd $6,764 - 0
93.286 Multi-Voxel Spectral Editing at 3t $6,521 - 0
93.866 Phase Ll/lll Trial for Slowing Progression in Mild Cognitive Impairment $6,504 - 0
93.242 Brain Glutomine Metabolism in Schizophrenia $5,540 - 0
93.865 Mri Biosensors and Complementary Drug Nonocarriers for Effective Image Guided Drug Delivery $5,097 - 0
93.853 Analysis of Dars2 in Leukoencephalopathy with Brainstem $4,949 - 0
12.420 Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease $4,843 - 0
93.113 Investigating Air Pollution Effects on the Developing Brain and Asd $4,830 - 0
93.286 Neurodegenerative and Neurodevelopmental Subcortical Shape Diff $4,626 - 0
93.877 Ut2 Autism Intervention Research $4,584 - 0
93.242 Oxidative Stree and Bipolar Disorder Trajectories $4,572 - 0
93.173 Research Related to Deafness & Communication Disorders $4,390 - 0
93.866 Mechanism of Pathologic Tau Fibrils Neuron to Neuron Transmission $4,365 - 0
93.866 Heterochronic Blood Exchange Inhibits Synucleinopathy $4,210 - 0
93.866 Neural Network Connectivity of Financial Capacity in Mild Cognitive Impairment $3,780 - 0
93.866 Early Onset Ad Consortium - Leads $3,402 - 0
93.350 Johns Hopkins Institute for Clinical Translational Research $3,261 - 0
93.837 Non-Contrast Enhanced Peripheral Mr Angiography $3,064 - 0
93.839 Mri-Based Quantitative Brain Oximetry for Sickle Cell Disease $1,912 - 0
93.242 Investigation of Cerebullar Involvement in Cognitive Function $1,909 - 0
93.853 Lymphocyte Cpg Methylation Changes and Brain Pathology in Restless Leg Syndrome $1,701 - 0
93.865 The Role of Executive Functions in Reading & Reading Remediation $1,492 - 0
93.242 Feasibility, Acceptability, and Preliminary Efficacy Ot Text4father for Improving Infant & Family Health $1,241 - 0
93.847 Dorsomedial Hypothalamic Signaling Pathways & Energy Balance $1,134 - 0
93.279 Drug Abuse & Addiction Research Program $1,094 - 0
93.865 Reliable Sensor Technology-Based for Rehabilitation $432 - 0
84.324A Efficacy Trial of Early Achievements Comp Intervention Preschoolers with Autism $355 - 0
84.419 Preschool Development $250 - 0
93.243 Family Informed Trauma Treatment Ctr-Fitt $190 - 0
93.865 Delineating Subypes of Self-Injurious Behavior Maintained by Automatic $188 - 0
93.853 Development of Dendrimer N Acctylcysteine for the Treatment of Neonatal Brain Injury $145 - 0
93.242 Virtual Brain Electrode (vibe) for Imaging Neuronal Activity $-56 - 0
93.853 Targeting Taz-Driven Oncogenic Signaling in Medulloblastoma $-64 - 0
32.006 Covid-19 - Telecommunications and Equipment $-512 - 0
93.865 Biomarkers for Therapy of Fshd (u54) $-1,282 - 0
93.286 Simultaneous Hadamard Editing of Gaba and Glutathione $-1,555 - 0
93.846 Functional & Molecular Properties of Pax7 $-4,226 - 0
93.853 Targeted Therapies for Rett Syndrome $-4,616 - 0
93.394 Highly Accelerated Chemical Exchange Saturation Transfer Mri Using Compresse Sensing $-7,296 - 0
93.865 Human Locomotors Plasticity in Health and Disease $-12,435 - 0
93.853 Methyl-Cpg-Dependent Transcription Factor Function in Human Glioma $-12,449 - 0
93.866 Leveraging Energetics to Improve Gait Rehabilitation After Stroke $-14,947 - 0
93.853 Cerebrovascular Abnormalities in Huntingtons Disease $-25,848 - 0

Contacts

Name Title Type
DKMDCB5HNBL7 Michael Neuman Auditee
4439231809 Victoria Brennan Auditor
No contacts on file

Notes to SEFA

Title: DEPARTMENT OF HEATH AND HUMAN SERVICES PROVIDER RELIEF FUNDS Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Schedule) summarizes the expenditures of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute") under programs of the Federal Government for the year ended June 30, 2022. The information presented in the Schedule is presented on the accrual basis of accounting, which is in accordance with the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Expenditures for federal awards are determined using the cost principles set forth in the Uniform Guidance. Under these cost principles, certain types of expenditures are not allowable or are limited to reimbursement. The accompanying Schedule includes the federal grant transactions of the Institute and includes Federal Awards made to the following corporate entities: Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education &Community Services, Inc. and PACT: Helping Children with Special Needs, Inc. under programs of the federal government for the year ended June 30, 2022. These corporate entities are denoted on the Schedule as follows: Total Federal Expenditures Passed to Subrecipients R $26,872,477 $3,463,415 C 4,531,273 - P 1,441,431 - H 6,968,960 - R Hugo W. Moser Research Institute at Kennedy Krieger, Inc. H Kennedy Krieger Childrens Hospital, Inc. C Kennedy Krieger Education & Community Services, Inc. P PACT: Helping Children with Special Needs, Inc. Because the Schedule presents only a selected portion of the operations of the Institute, it is not intended to and does not present the financial position, results of operations and non-operating activity, or cash flows of the Institute. Negative amounts reflect adjustments made to expenditures reported in prior years in the normal course of business. For purposes of the Schedule, federal awards include all awards in the form of grants, contracts, and similar agreements entered into directly between the Institute and agencies and departments of the federal government, or non-federal pass-through entities. Federal Assistance Listing Numbers and pass-through identification numbers are included when available. De Minimis Rate Used: Y Rate Explanation: The Schedule reflects federal award program expenditures recognized on the accrual basis ofaccounting in accordance with accounting principles generally accepted in the United States ofAmerica. The Institute has not elected to use the 10% de minimis rate for indirect costs. Indirect costsare billed based upon negotiated and budgeted rates. The Schedule includes grant activity related to the Department of Health and Human Services(HHS) Provider Relief Fund and American Rescue Plan (ARP) Distribution Assistance Listing Number 93.498. As required based on guidance in the 2022 OMB Compliance Supplement, the Schedule includes all Period 2 funds received between July 1, 2020 to December 31, 2020 and expended by December 31, 2021 as reported to HRSA via the PRF Reporting Portal. The Schedule thus includes $1,560,903 of direct expenditures and $3,497,424 in lost revenue. Lost revenue does not represent an expenditure in the Institutes financial statements and thus is a reconciling item between the federal expenses in the financial statements and the amount included on the Schedule.

Finding Details

2022-001: Lost Revenues Reporting Methodology Cluster: Not applicable Federal Granting Agency: Health Resources and Services Administration Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution ? Period 2 Assistance Listing #: 93.498 Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) RuralDistribution ? Period 2 Award Year: January 1, 2020 ? June 30, 2022 Criteria Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund(PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues: ? Option (i): difference between actual patient care revenues; ? Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient carerevenues; or ? Option (iii): calculated by any reasonable method of estimating revenues Condition The Company calculated the portion of its Period 2 PRF payments applied toward lost revenues usingOption (iii); however, the Company completed its Period 2 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i). Cause The Company did not interpret the HRSA PRF Reporting instructions correctly therefore attested to usingOption (i) in its Period 2 PRF Reporting Portal submissions. Effect The Company incorrectly attested to the methodology utilized to calculate lost revenue in accordance withthe June 11, 2021 PRF General and Targeted Distribution Post-Payment Notice of Reporting Requirements. In addition, as required by the Health Resources & Services Administrator (HRSA) when Option (iii) is utilized, information used to support the methodology used was not provided to HRSA when the portal reporting was submitted. This is a repeat finding from the prior year. Questioned Costs None noted. Recommendation We recommend the Company contact the Health Resources & Services Administrator (HRSA) to determine any required corrective actions related to the incorrect reporting. Management?s Views and Corrective Action Plan Management?s response is included in ?Management?s Views and Corrective Action Plan? included at the end of this report.
2022-001: Lost Revenues Reporting Methodology Cluster: Not applicable Federal Granting Agency: Health Resources and Services Administration Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution ? Period 2 Assistance Listing #: 93.498 Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) RuralDistribution ? Period 2 Award Year: January 1, 2020 ? June 30, 2022 Criteria Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund(PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues: ? Option (i): difference between actual patient care revenues; ? Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient carerevenues; or ? Option (iii): calculated by any reasonable method of estimating revenues Condition The Company calculated the portion of its Period 2 PRF payments applied toward lost revenues usingOption (iii); however, the Company completed its Period 2 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i). Cause The Company did not interpret the HRSA PRF Reporting instructions correctly therefore attested to usingOption (i) in its Period 2 PRF Reporting Portal submissions. Effect The Company incorrectly attested to the methodology utilized to calculate lost revenue in accordance withthe June 11, 2021 PRF General and Targeted Distribution Post-Payment Notice of Reporting Requirements. In addition, as required by the Health Resources & Services Administrator (HRSA) when Option (iii) is utilized, information used to support the methodology used was not provided to HRSA when the portal reporting was submitted. This is a repeat finding from the prior year. Questioned Costs None noted. Recommendation We recommend the Company contact the Health Resources & Services Administrator (HRSA) to determine any required corrective actions related to the incorrect reporting. Management?s Views and Corrective Action Plan Management?s response is included in ?Management?s Views and Corrective Action Plan? included at the end of this report.
2022-001: Lost Revenues Reporting Methodology Cluster: Not applicable Federal Granting Agency: Health Resources and Services Administration Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution ? Period 2 Assistance Listing #: 93.498 Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) RuralDistribution ? Period 2 Award Year: January 1, 2020 ? June 30, 2022 Criteria Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund(PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues: ? Option (i): difference between actual patient care revenues; ? Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient carerevenues; or ? Option (iii): calculated by any reasonable method of estimating revenues Condition The Company calculated the portion of its Period 2 PRF payments applied toward lost revenues usingOption (iii); however, the Company completed its Period 2 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i). Cause The Company did not interpret the HRSA PRF Reporting instructions correctly therefore attested to usingOption (i) in its Period 2 PRF Reporting Portal submissions. Effect The Company incorrectly attested to the methodology utilized to calculate lost revenue in accordance withthe June 11, 2021 PRF General and Targeted Distribution Post-Payment Notice of Reporting Requirements. In addition, as required by the Health Resources & Services Administrator (HRSA) when Option (iii) is utilized, information used to support the methodology used was not provided to HRSA when the portal reporting was submitted. This is a repeat finding from the prior year. Questioned Costs None noted. Recommendation We recommend the Company contact the Health Resources & Services Administrator (HRSA) to determine any required corrective actions related to the incorrect reporting. Management?s Views and Corrective Action Plan Management?s response is included in ?Management?s Views and Corrective Action Plan? included at the end of this report.
2022-001: Lost Revenues Reporting Methodology Cluster: Not applicable Federal Granting Agency: Health Resources and Services Administration Award Name: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution ? Period 2 Assistance Listing #: 93.498 Assistance Listing Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) RuralDistribution ? Period 2 Award Year: January 1, 2020 ? June 30, 2022 Criteria Step Six of the Steps on Reporting on Use of Funds section of the June 11, 2021 Provider Relief Fund(PRF) General and Targeted Distribution Post-Payment Notice of Reporting Requirements requires recipients that apply PRF payments toward lost revenues to use one of the following three options for calculating lost revenues: ? Option (i): difference between actual patient care revenues; ? Option (ii): difference between budgeted (prior to March 27, 2020) and actual patient carerevenues; or ? Option (iii): calculated by any reasonable method of estimating revenues Condition The Company calculated the portion of its Period 2 PRF payments applied toward lost revenues usingOption (iii); however, the Company completed its Period 2 PRF Reporting Portal submissions and attested to calculating lost revenues using Option (i). Cause The Company did not interpret the HRSA PRF Reporting instructions correctly therefore attested to usingOption (i) in its Period 2 PRF Reporting Portal submissions. Effect The Company incorrectly attested to the methodology utilized to calculate lost revenue in accordance withthe June 11, 2021 PRF General and Targeted Distribution Post-Payment Notice of Reporting Requirements. In addition, as required by the Health Resources & Services Administrator (HRSA) when Option (iii) is utilized, information used to support the methodology used was not provided to HRSA when the portal reporting was submitted. This is a repeat finding from the prior year. Questioned Costs None noted. Recommendation We recommend the Company contact the Health Resources & Services Administrator (HRSA) to determine any required corrective actions related to the incorrect reporting. Management?s Views and Corrective Action Plan Management?s response is included in ?Management?s Views and Corrective Action Plan? included at the end of this report.